Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.
Advanced/Metastatic Solid Tumors or Lymphomas
DRUG: ADU-S100|BIOLOGICAL: ipilimumab
Safety: Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities, Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities, 6 months from study start|Recommended dose, Using maximum tolerated dose to identify the recommended dose for future studies, 6 months from study start
Pharmacokinetics measured through plasma concentrations, measured through plasma concentrations, 6 months from study start|measurement of CD8-TIL counts, 6 months from study start|RNA expression analysis of IFN gamma and immunomodulatory genes, 6 months from study start
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.